Supplementary file

Suppl. Table S1. Demographic, laboratory features and ECG parameters of controls and RA patients in the sample with electrolytes.

	Controls n=236	RA n=154	*p*-value
Age, years	60.4 ± 9.3	60.7 ± 9.7	0.77
Female, n(%)	157 (66.5)	124 (80.5)	0.003
Hypertension , n(%)	77 (32.6)	62 (40.3)	0.12
Dyslipidemia, n(%)	65 (27.5)	40 (26)	0.73
Diabetes, n(%)	18 (7.6)	9 (5.8)	0.49
Current smoker, n(%)	40 (16.9)	34 (22.1)	0.20
Serum potassium, mEq/L	4.3 ± 0.5	4.2 ± 0.4	0.03
Serum calcium, mg/dl	9.2 ± 0.5	9.2 ± 0.4	0.98
Hypokalaemia, n(%)*	12 (5.1)	10 (6.5)	0.55
Hypocalcaemia, n(%)*	33 (14)	19 (12.8)	0.71
Heart rate, bpm	75 ± 12	70 ± 10	<0.001
QTc, msec	408 ± 29	418 ± 30	<0.001
Prolonged QTc, n(%)	17 (7.2)	15 (9.7)	0.37
Marked QTc prolongation, %	5 (2.1)	6 (3.9)	0.30
QTd, msec	38.1 ± 15.8	47.9 ± 24.9	<0.001
Prolonged QTd, %	51 (21.6)	63 (40.9)	<0.001

Values are mean ± SD.
bpm, beat per minute; Marked QTc prolongation, QTc ≥500 msec; msec, milliseconds; Prolonged QTc, QTC ≥450 msec in males and ≥460 msec in females; Prolonged QTd, QTd ≥60 msec.

Suppl. Table S2. Rheumatoid arthritis specific risk factors for prolonged QTd interval.

Risk factor	OR	(95%CI)	*p*-value
DAS-28	0.98	(0.86-1.10)	0.76
HAQ	0.89	(0.70-1.14)	0.38
ACPA	1.00	(0.69-1.45)	0.98
RF	0.87	(0.60-1.27)	0.49
CRP	0.99	(0.96-1.02)	0.78
ESR	0.99	(0.98-1.00)	0.13
Disease duration	1.00	(0.99-1.00)	0.33
Steroid use	0.96	(0.69-1.35)	0.83
DMARDs use	0.93	(0.63-1.37)	0.73
TNFi use	1.04	(0.71-1.50)	0.83
Tocilizumab use	0.62	(0.31-1.26)	0.19

Odds ratio (OR) is based on the risk of the dependent variable (prolonged QTd), given the presence of the independent variable. 95%CI: 95% confidence interval; DAS-28: Disease Activity Score 28-joints; HAQ: Health Assessment Questionnaire; ACPA: anti citrullinated peptide antibodies positivity; RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DMARDs: disease-modifying anti-rheumatic drugs; TNFi: tumour necrosis factor alpha inhibitors.